Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | MCHR1 | Q99705 | 4/20 | 0.34 |
| ▸ | PGR | P06401 | 1/20 | 0.32 |
| ▸ | NCF1 | P14598 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | NOS3 | P29474 | 1/20 | 0.31 |
| ▸ | NOS1 | P29475 | 1/20 | 0.31 |
| ▸ | NOS2 | P35228 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26347919 | 0.91 | KDM4E (0.38) | MCHR1NCF1KDM4EALDH1A1NOS3 | |
| SCHEMBL26762607 | 0.84 | NCF1 (0.41) | NCF1KDM4EALDH1A1NOS3NOS1 | |
| SCHEMBL23603454 | 0.83 | SIGMAR1 (0.38) | SIGMAR1MCHR1PGRNCF1KDM4E | |
| SCHEMBL13046392 | 0.83 | KDM4E (0.41) | MCHR1NCF1KDM4EALDH1A1NOS3 | |
| SCHEMBL10202213 | 0.79 | NCF1 (0.46) | NCF1KDM4EALDH1A1NOS3NOS1 | |
| SCHEMBL14396577 | 0.78 | TMEM97 (0.33) | — | |
| SCHEMBL26762608 | 0.78 | — | — | |
| SCHEMBL12717990 | 0.76 | NCF1 (0.41) | NCF1KDM4EALDH1A1NOS3NOS1 | |
| SCHEMBL24319183 | 0.76 | NCF1 (0.41) | NCF1KDM4EALDH1A1NOS3NOS1 | |
| SCHEMBL10202212 | 0.76 | NCF1 (0.43) | NCF1KDM4EALDH1A1NOS3NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365562-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365562-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | SIGMAR1 3199/4885MCHR1 3799/4885PGR 2344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.